A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

← catalyst calendar

NCT07094204 · readout in 833 d

Sponsored by Astellas Pharma Inc (industry) · 4503.T — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

364estimated

Sites

Countries

France, Japan, Spain +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-07-25

actual

When the study began enrolling

Primary completion

2028-11-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2029-04-30

estimated

The whole study's end, after follow-up

First posted

2025-07-30

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-18

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Solid Tumor
Non-Small-Cell Lung Cancer
Pancreatic Ductal Adenocarcinoma
Colorectal Cancer

Interventions

Drug: ASP5834
Drug: panitumumab

Primary outcomes

what the primary-completion date above is the date OF

Incidence of Dose Limiting Toxicities (DLTs) (Dose Escalation only)

measured Up to 21 days

Number of participants with Adverse Events (AEs)

measured Up to 40 months

Number of Participants with Serious Adverse Events (SAEs)

measured Up to 40 months

Number of participants with laboratory value abnormalities and/or adverse events (AEs)

measured Up to 40 months

Number of Participants with Eye Exam abnormalities and/or Adverse Events (AEs)

measured Up to 39 months

Number of participants with electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)

measured Up to 39 months

Number of participants with vital sign abnormalities and/or adverse events (AEs)

measured Up to 40 months

Number of participants with echocardiogram (ECHO) abnormalities and/or adverse events (AEs)

measured Up to 39 months

Number of participants with multigated acquisition (MUGA) abnormalities and/or adverse events (AEs)

measured Up to 39 months

Number of Participants with Physical Examination (PE) abnormalities and/or AEs

measured Up to 40 months

Number of Participants at each grade of Eastern Cooperative Oncology Group (ECOG) performance status scores

measured Up to 40 months

Permalink · 4503.T's whole pipeline · Catalyst calendar · Every registered study · What changed